계명대학교 의학도서관 Repository

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)

Metadata Downloads
Author(s)
Hyeon-Seok EomYeo-Kyeoung KimJoo-Seop ChungKihyun KimHyo Jung KimHo Young Kim & Jong-Youl JinYoung-Rok DoSuk-Joong OhCheolwon SuhChu-Myong SeongChul Soo KimDong Soon LeeJae Hoon Lee
Publication Year
2010
Abstract
Bortezomib (VELCADE®), thalidomide and
dexamethasone (VTD), as well as melphalan, prednisolone,
and thalidomide (MPT) therapy, are highly effective in
patients with multiple myeloma. We evaluated the responses
and survival times of 35 patients treated with VTD followed
by MPT. All patients were newly diagnosed and nontransplantation
candidates. Patients received six cycles of
VTD, which were followed by eight cycles of MPT.
Approximately 97% of patients exhibited early responses
to therapy, as early as the second cycle of VTD. Thirty
percent of the responses were high quality, which was
defined as a complete response (CR), a near-CR or a verygood partial response. High-risk patients were defined as
patients with any of the following aberrations: del(13),
t(4;14), or del(17p). The remaining patients were defined as
standard risk. Eleven high-risk patients showed 100%
response rates, including 91% high-quality responses. In
contrast, 13 standard-risk patients exhibited 92% response
rates, including 61% high-quality responses. The overall
2-year survival rates were 60% in high-risk patients and 85%
in standard-risk patients, which was not significantly
different. As a first-line therapy, VTD followed by MPT
has the potential to provide high-quality responses with
durable remission among elderly and high-risk patients
(clinicaltrials.gov identifier: NCT00320476).
Keywords Multiple myeloma . Bortezomib . Thalidomide .
High-risk . Elderly patients
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Annals of Hematology, Vol.89(5) : 489-97, 2010
Type
Article
ISSN
0939-5555
DOI
10.1007/s00277-009-0871-y
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/34967
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.